MedTrace Logo

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population

NCT04626024 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2026-05-04

No results posted yet for this study

Summary

This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population.

Conditions

  • Chronic Myeloid Leukemia
  • Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission
  • Chronic Myeloid Leukemia in Remission

Interventions

OTHER

Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal

Stop taking TKI medication

DRUG

Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation

Re-start TKI medication

Sponsors & Collaborators

  • Baylor College of Medicine

    lead OTHER

Principal Investigators

  • Martha P. Mims, MD, PhD · Baylor College of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-22
Primary Completion
2028-11-15
Completion
2028-11-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04626024 on ClinicalTrials.gov